Tonix Discontinues Development For Fibromyalgia Drug After Phase 3 Trial Fails
News
New York based Tonix Pharmaceuticals announced it will halt the development of its TNX-102 SL drug candidate for the treatment of fibromyalgia after it failed to achieve target endpoints in the ... Read more